Levels of α7 integrin and laminin-α2 are increased following prednisone treatment in the mdx mouse and GRMD dog models of Duchenne muscular dystrophy

DMM Disease Models and Mechanisms

Volumn 6, Issue 5, 2013, Pages 1175-1184

  Wuebbles, Ryan D ^a   Sarathy, Apurva ^a   Kornegay, Joe N ^b   Burkin, Dean J ^a  

^a UNIVERSITY OF NEVADA SCHOOL OF MEDICINE   (United States)

^b TEXAS A AND M UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA7 INTEGRIN; LAMININ ALPHA2; MEROSIN; PREDNISONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE MODEL; DOG; DRUG MECHANISM; DUCHENNE MUSCULAR DYSTROPHY; GENE; HUMAN; HUMAN CELL; MDX GENE; MOUSE; MUSCLE; MUSCLE CELL; MYOGENIC CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN LOCALIZATION;

ANIMALS; ANTIGENS, CD; DISEASE MODELS, ANIMAL; DOGS; GENE EXPRESSION REGULATION; HUMANS; INTEGRIN ALPHA CHAINS; LAMININ; MICE; MICE, INBRED MDX; MODELS, BIOLOGICAL; MUSCLE FIBERS, SKELETAL; MUSCLE, SKELETAL; MUSCULAR DYSTROPHY, ANIMAL; MUSCULAR DYSTROPHY, DUCHENNE; MYOBLASTS; PREDNISONE; RNA STABILITY; RNA, MESSENGER;

EID: 84883870224     PISSN: 17548403     EISSN: 17548411     Source Type: Journal    
DOI: 10.1242/dmm.012211     Document Type: Article

References (33)

1. Anderson, J. E., Weber, M. and Vargas, C. (2000). Deflazacort increases laminin expression and myogenic repair, and induces early persistent functional gain in mdx mouse muscular dystrophy. Cell Transplant. 9, 551-564.
2. Angelini, C., Pegoraro, E., Turella, E., Intino, M. T., Pini, A. and Costa, C. (1994). Deflazacort in Duchenne dystrophy: study of long-term effect. Muscle Nerve 17, 386-391.
3. Beenakker, E. A., Fock, J. M., Van Tol, M. J., Maurits, N. M., Koopman, H. M., Brouwer, O. F. and Van der Hoeven, J. H. (2005). Intermittent prednisone therapy in Duchenne muscular dystrophy: a randomized controlled trial. Arch. Neurol. 62, 128-132.
4. Boppart, M. D., Burkin, D. J. and Kaufman, S. J. (2006). α7β1-Integrin regulates mechanotransduction and prevents skeletal muscle injury. Am. J. Physiol. 290, C1660-C1665.
5. Bulfield, G., Siller, W. G., Wight, P. A. and Moore, K. J. (1984). X chromosome-linked muscular dystrophy (mdx) in the mouse. Proc. Natl. Acad. Sci. USA 81, 1189-1192.
6. Burkin, D. J. and Kaufman, S. J. (1999). The alpha7beta1 integrin in muscle development and disease. Cell Tissue Res. 296, 183-190.
7. Burkin, D. J., Wallace, G. Q., Nicol, K. J., Kaufman, D. J. and Kaufman, S. J. (2001). Enhanced expression of the alpha 7 beta 1 integrin reduces muscular dystrophy and restores viability in dystrophic mice. J. Cell Biol. 152, 1207-1218.
8. Burkin, D. J., Wallace, G. Q., Milner, D. J., Chaney, E. J., Mulligan, J. A. and Kaufman, S. J. (2005). Transgenic expression of alpha7beta1 integrin maintains muscle integrity, increases regenerative capacity, promotes hypertrophy, and reduces cardiomyopathy in dystrophic mice. Am. J. Pathol. 166, 253-263.
9. Cooper, B. J., Winand, N. J., Stedman, H., Valentine, B. A., Hoffman, E. P., Kunkel, L. M., Scott, M. O., Fischbeck, K. H., Kornegay, J. N., Avery, R. J. et al. (1988). The homologue of the Duchenne locus is defective in X-linked muscular dystrophy of dogs. Nature 334, 154-156.
10. Doe, J. A., Wuebbles, R. D., Allred, E. T., Rooney, J. E., Elorza, M. and Burkin, D. J. (2011). Transgenic overexpression of the α7 integrin reduces muscle pathology and improves viability in the dy(W) mouse model of merosin-deficient congenital muscular dystrophy type 1A. J. Cell Sci. 124, 2287-2297.
11. Fenichel, G. M., Florence, J. M., Pestronk, A., Mendell, J. R., Moxley, R. T., 3rd, Griggs, R. C., Brooke, M. H., Miller, J. P., Robison, J., King, W. et al. (1991). Longterm benefit from prednisone therapy in Duchenne muscular dystrophy. Neurology 41, 1874-1877.
12. Flintoff-Dye, N. L., Welser, J., Rooney, J., Scowen, P., Tamowski, S., Hatton, W. and Burkin, D. J. (2005). Role for the alpha7beta1 integrin in vascular development and integrity. Dev. Dyn. 234, 11-21.
13. Guo, C., Willem, M., Werner, A., Raivich, G., Emerson, M., Neyses, L. and Mayer, U. (2006). Absence of alpha 7 integrin in dystrophin-deficient mice causes a myopathy similar to Duchenne muscular dystrophy. Hum. Mol. Genet. 15, 989-998.
14. Gurpur, P. B., Liu, J., Burkin, D. J. and Kaufman, S. J. (2009). Valproic acid activates the PI3K/Akt/mTOR pathway in muscle and ameliorates pathology in a mouse model of Duchenne muscular dystrophy. Am. J. Pathol. 174, 999-1008.
15. Hayashi, Y. K., Chou, F. L., Engvall, E., Ogawa, M., Matsuda, C., Hirabayashi, S., Yokochi, K., Ziober, B. L., Kramer, R. H., Kaufman, S. J. et al. (1998). Mutations in the integrin alpha7 gene cause congenital myopathy. Nat. Genet. 19, 94-97.
16. Hodges, B. L., Hayashi, Y. K., Nonaka, I., Wang, W., Arahata, K. and Kaufman, S. J. (1997). Altered expression of the alpha7beta1 integrin in human and murine muscular dystrophies. J. Cell Sci. 110, 2873-2881.
17. Hoffman, E. P., Brown, R. H., Jr and Kunkel, L. M. (1987). Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell 51, 919-928.
18. Kornegay, J. N., Tuler, S. M., Miller, D. M. and Levesque, D. C. (1988). Muscular dystrophy in a litter of golden retriever dogs. Muscle Nerve 11, 1056-1064.
19. Kornegay, J. N., Bogan, J. R., Bogan, D. J., Childers, M. K., Li, J., Nghiem, P., Detwiler, D. A., Larsen, C. A., Grange, R. W., Bhavaraju-Sanka, R. K. et al. (2012). Canine models of Duchenne muscular dystrophy and their use in therapeutic strategies. Mamm. Genome 23, 85-108.
20. Liu, J. M., Okamura, C. S., Bogan, D. J., Bogan, J. R., Childers, M. K. and Kornegay, J. N. (2004). Effects of prednisone in canine muscular dystrophy. Muscle Nerve 30, 767-773.
21. Liu, J., Burkin, D. J. and Kaufman, S. J. (2008a). Increasing alpha 7 beta 1-integrin promotes muscle cell proliferation, adhesion, and resistance to apoptosis without changing gene expression. Am. J. Physiol. 294, C627-C640.
22. Liu, J., Gurpur, P. B. and Kaufman, S. J. (2008b). Genetically determined proteolytic cleavage modulates alpha7beta1 integrin function. J. Biol. Chem. 283, 35668-35678.
23. Martin, P. T., Kaufman, S. J., Kramer, R. H. and Sanes, J. R. (1996). Synaptic integrins in developing, adult, and mutant muscle: selective association of alpha1, alpha7A, and alpha7B integrins with the neuromuscular junction. Dev. Biol. 174, 125-139.
24. Masuda, S., Hayashi, T., Hashimoto, T. and Taguchi, S. (2009). Correlation of dystrophin-glycoprotein complex and focal adhesion complex with myosin heavy chain isoforms in rat skeletal muscle. Acta Physiol. (Oxf.) 195, 483-494.
25. Mayer, U., Saher, G., Fässler, R., Bornemann, A., Echtermeyer, F., von der Mark, H., Miosge, N., Pöschl, E. and von der Mark, K. (1997). Absence of integrin alpha 7 causes a novel form of muscular dystrophy. Nat. Genet. 17, 318-323.
26. Merlini, L., Cicognani, A., Malaspina, E., Gennari, M., Gnudi, S., Talim, B. and Franzoni, E. (2003). Early prednisone treatment in Duchenne muscular dystrophy. Muscle Nerve 27, 222-227.
27. Monaco, A. P., Neve, R. L., Colletti-Feener, C., Bertelson, C. J., Kurnit, D. M. and Kunkel, L. M. (1986). Isolation of candidate cDNAs for portions of the Duchenne muscular dystrophy gene. Nature 323, 646-650.
28. Pichavant, C., Aartsma-Rus, A., Clemens, P. R., Davies, K. E., Dickson, G., Takeda, S., Wilton, S. D., Wolff, J. A., Wooddell, C. I., Xiao, X. et al. (2011). Current status of pharmaceutical and genetic therapeutic approaches to treat DMD. Mol. Ther. 19, 830-840.
29. Reitter, B. (1995). Deflazacort vs. prednisone in Duchenne muscular dystrophy: trends of an ongoing study. Brain Dev. 17 Suppl., 39-43.
30. Rooney, J. E., Welser, J. V., Dechert, M. A., Flintoff-Dye, N. L., Kaufman, S. J. and Burkin, D. J. (2006). Severe muscular dystrophy in mice that lack dystrophin and alpha7 integrin. J. Cell Sci. 119, 2185-2195.
31. Rooney, J. E., Gurpur, P. B. and Burkin, D. J. (2009). Laminin-111 protein therapy prevents muscle disease in the mdx mouse model for Duchenne muscular dystrophy. Proc. Natl. Acad. Sci. USA 106, 7991-7996.
32. Sali, A., Guerron, A. D., Gordish-Dressman, H., Spurney, C. F., Iantorno, M., Hoffman, E. P. and Nagaraju, K. (2012). Glucocorticoid-treated mice are an inappropriate positive control for long-term preclinical studies in the mdx mouse. PLoS ONE 7, e34204.
33. Song, W. K., Wang, W., Sato, H., Bielser, D. A. and Kaufman, S. J. (1993). Expression of alpha 7 integrin cytoplasmic domains during skeletal muscle development: alternate forms, conformational change, and homologies with serine/threonine kinases and tyrosine phosphatases. J. Cell Sci. 106, 1139-1152.